- Year over year fourth quarter revenue increases 100%
- Year over year fourth quarter net income increases 192%
- During 2016, Company pays down $11.7 million on its credit facility
- Company continues to pay regular quarterly cash dividend of $0.05 cents per share
SUWANEE, Ga., Feb. 24, 2017 (GLOBE NEWSWIRE) -- Digirad Corporation (Nasdaq:DRAD) today reported its financial results for the fourth quarter and twelve months ended December 31, 2016.
Total revenues for the fourth quarter were $31.1 million, an increase of 100 percent compared to the prior year’s fourth quarter revenues of $15.6 million.
Net income for the fourth quarter was $2.0 million, or $0.10 diluted earnings per share (EPS), compared to net income of $0.7 million, or $0.03 diluted EPS from the same period in the prior year. Non-GAAP adjusted net income for the fourth quarter was $3.0 million, or $0.15 diluted EPS, compared to $1.3 million, or $0.07 diluted EPS from the same period in the prior year.
Non-GAAP adjusted EBITDA for the fourth quarter was $5.4 million, compared to $2.1 million in the same period in the prior year.
Total revenues for the twelve months ended December 31, 2016 were $125.5 million, an increase of 106 percent compared to the prior year’s revenues of $60.8 million.
Net income for the twelve months ended December 31, 2016 was $14.3 million, or $0.71 diluted EPS, compared to net income of $21.6 million, or $1.10 diluted EPS in the same period in the prior year. Non-GAAP adjusted net income for the twelve months ended December 31, 2016 was $7.2 million, or $0.36 diluted EPS, compared to non-GAAP adjusted net income of $4.5 million, or $0.23 diluted EPS in the same period in the prior year.
Non-GAAP adjusted EBITDA for the twelve months ended December 31, 2016 was $16.8 million, compared to $7.2 million in the same period in the prior year. A reconciliation of non-GAAP adjusted net income and non-GAAP adjusted EBITDA is provided later in this release.
The results for the fourth quarter and twelve months ended December 31, 2016 include the results of the recent acquisition of DMS Health, which closed on January 1, 2016.
Digirad President and CEO Matt Molchan said, “We are very pleased with our results for the quarter, where we experienced exceptional product sales performance, as well as great performance from our service businesses, capping off a transformational year for Digirad.”
Molchan continued, “I am also pleased to report we have completed all of our operational integration activities related to the DMS Health acquisition, and will now be focusing our efforts on leveraging our combined resources as we move forward. Additionally, since entering our credit facility at the beginning of the year, we have paid down $11.7 million of the initial balance, including three extra principal payments. We continue to generate significant cash flow to maintain our stable dividend, fund organic growth and pursue accretive acquisitions.”
The Company previously announced a cash dividend of $0.05 cents per share that will be paid on February 28, 2017, to shareholders of record on February 15, 2017.
Conference Call Information
A conference call is scheduled for 10:00 a.m. EST on February 24, 2017 to discuss the results and management's outlook. The call may be accessed by dialing 1-877-407-9039 (international callers: +1-201-689-8470) five minutes prior to the scheduled start time and referencing Digirad. A simultaneous webcast of the call may be accessed online from the Events & Presentations link on the Investor Relations page at http://drad.client.shareholder.com; an archived replay of the webcast will be available within 15 minutes of the end of the conference call.
Use of Non-GAAP Financial Measures by Digirad Corporation
This Digirad news release presents the non-GAAP financial measures “adjusted net income,” “adjusted net income per diluted share,” and “adjusted EBITDA.” The most directly comparable measure for these non-GAAP financial measures are net income and diluted net income per share. The Company has included below unaudited adjusted financial information, which presents the Company's results of operations after excluding acquired intangible asset amortization, goodwill impairment, acquisition related contingent consideration adjustments, investment impairment loss, transaction and integration costs associated with DMS Health Technologies, and non-recurring related income tax adjustments. Further excluded in the measure of adjusted EBITDA are interest, taxes, depreciation, amortization and stock-based compensation.
A discussion of the reasons why management believes that the presentation of non-GAAP financial measures provides useful information to investors regarding Digirad's financial condition and results of operations is included as Exhibit 99.2 to Digirad's report on Form 8-K filed with the Securities and Exchange Commission on February 24, 2017.
About Digirad Corporation
Digirad delivers convenient, effective, and efficient healthcare solutions on an as needed, when needed, and where needed basis. Digirad’s diverse portfolio of mobile healthcare solutions and medical equipment and services, including diagnostic imaging and patient monitoring, provides hospitals, physician practices, and imaging centers through the United States access to technology and services necessary to provide exceptional patient care in the rapidly changing healthcare environment. For more information, please visit www.digirad.com.
Forward-Looking Statements
This press release contains statements that are forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995. Some of these forward-looking statements can be identified by the use of forward-looking words such as “believes,” “expects,” “may,” “will,” “should,” “seek,” “approximately,” “intends,” “plans,” “estimates,” or “anticipates,” or the negative of those words or other comparable terminology, or in specific statements such as the Company's ability to deliver value to customers, the ability to grow and generate positive cash flow, the ability to execute on restructuring activities, and ability to successfully execute acquisitions. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from the statements made. These risks are detailed in Digirad's filings with the U.S. Securities and Exchange Commission, including the Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other reports. Readers are cautioned to not place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Digirad undertakes no obligation to revise or update the forward-looking statements contained herein.
(Financial tables follow)
| Digirad Corporation Consolidated Statements of Operations (Unaudited) | |||||||||||||||
| Three Months Ended | Twelve Months Ended | ||||||||||||||
| December 31, | December 31, | ||||||||||||||
| (in thousands, except per share amounts) | 2016 | 2015 | 2016 | 2015 | |||||||||||
| Revenues: | |||||||||||||||
| Services | $ | 23,015 | $ | 11,683 | $ | 95,511 | $ | 46,407 | |||||||
| Product and product-related | 8,119 | 3,895 | 29,956 | 14,419 | |||||||||||
| Total revenues | 31,134 | 15,578 | 125,467 | 60,826 | |||||||||||
| Cost of revenues: | |||||||||||||||
| Services | 18,720 | 9,048 | 75,515 | 35,968 | |||||||||||
| Product and product-related | 3,772 | 1,838 | 14,179 | 6,949 | |||||||||||
| Total cost of revenues | 22,492 | 10,886 | 89,694 | 42,917 | |||||||||||
| Gross profit | 8,642 | 4,692 | 35,773 | 17,909 | |||||||||||
| Total gross profit percentage | 27.8 | % | 30.1 | % | 28.5 | % | 29.4 | % | |||||||
| Services gross profit percentage | 18.7 | % | 22.6 | % | 20.9 | % | 22.5 | % | |||||||
| Product and product-related gross profit percentage | 53.5 | % | 52.8 | % | 52.7 | % | 51.8 | % | |||||||
| Operating expenses: | |||||||||||||||
| Marketing and sales | 2,161 | 1,051 | 10,049 | 4,741 | |||||||||||
| General and administrative | 4,088 | 3,009 | 19,988 | 9,888 | |||||||||||
| Amortization of intangible assets | 578 | 134 | 2,313 | 506 | |||||||||||
| Goodwill impairment | 338 | — | 338 | — | |||||||||||
| Total operating expenses | 7,165 | 4,194 | 32,688 | 15,135 | |||||||||||
| Income from operations | 1,477 | 498 | 3,085 | 2,774 | |||||||||||
| Other income (expense): | |||||||||||||||
| Other income (expense), net | 627 | (233 | ) | 212 | (233 | ) | |||||||||
| Interest expense, net | (320 | ) | (12 | ) | (1,412 | ) | (24 | ) | |||||||
| Total other income (expense) | 307 | (245 | ) | (1,200 | ) | (257 | ) | ||||||||
| Income before income taxes | 1,784 | 253 | 1,885 | 2,517 | |||||||||||
| Income tax benefit | 194 | 425 | 12,417 | 19,123 | |||||||||||
| Net income | $ | 1,978 | $ | 678 | $ | 14,302 | $ | 21,640 | |||||||
| Net income per share: | |||||||||||||||
| Basic | $ | 0.10 | $ | 0.03 | $ | 0.73 | $ | 1.13 | |||||||
| Diluted | $ | 0.10 | $ | 0.03 | $ | 0.71 | $ | 1.10 | |||||||
| Dividends declared per common share | $ | 0.05 | $ | 0.05 | $ | 0.20 | $ | 0.20 | |||||||
| Weighted average shares outstanding – basic | 19,764 | 19,404 | 19,594 | 19,210 | |||||||||||
| Weighted average shares outstanding – diluted | 20,173 | 19,933 | 20,067 | 19,690 | |||||||||||
| Digirad Corporation Consolidated Balance Sheets (Unaudited) | |||||||
| (in thousands) | December 31, 2016 | December 31, 2015 | |||||
| Assets: | |||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 2,203 | $ | 15,868 | |||
| Securities available-for-sale | 917 | 3,227 | |||||
| Accounts receivable, net | 14,503 | 7,274 | |||||
| Inventories, net | 5,987 | 4,381 | |||||
| Restricted cash | 1,376 | 233 | |||||
| Other current assets | 2,093 | 764 | |||||
| Total current assets | 27,079 | 31,747 | |||||
| Property and equipment, net | 31,407 | 6,252 | |||||
| Intangible assets, net | 11,628 | 3,079 | |||||
| Goodwill | 6,237 | 2,897 | |||||
| Deferred tax assets | 27,019 | 18,578 | |||||
| Restricted cash | 2,100 | — | |||||
| Other assets | 793 | 1,560 | |||||
| Total assets | $ | 106,263 | $ | 64,113 | |||
| Liabilities: | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ | 6,514 | $ | 1,369 | |||
| Accrued compensation | 3,962 | 2,453 | |||||
| Accrued warranty | 196 | 213 | |||||
| Deferred revenue | 3,123 | 1,673 | |||||
| Current portion of long-term debt | 5,358 | — | |||||
| Other current liabilities | 3,520 | 2,998 | |||||
| Total current liabilities | 22,673 | 8,706 | |||||
| Long-term debt, net of current portion | 16,070 | — | |||||
| Other liabilities | 1,039 | 1,252 | |||||
| Total liabilities | 39,782 | 9,958 | |||||
| Stockholders’ equity: | |||||||
| Preferred stock, $0.0001 par value: 10,000,000 shares authorized; no shares issued or outstanding | — | — | |||||
| Common stock, $0.0001 par value: 80,000,000 shares authorized; 19,892,557 and 19,416,070 shares issued and outstanding (net of treasury shares) at December 31, 2016 and 2015, respectively | 2 | 2 | |||||
| Treasury stock, at cost; 2,588,484 shares at December 31, 2016 and 2015 | (5,728 | ) | (5,728 | ) | |||
| Additional paid-in capital | 151,696 | 153,860 | |||||
| Accumulated other comprehensive loss | (52 | ) | (240 | ) | |||
| Accumulated deficit | (79,437 | ) | (93,739 | ) | |||
| Total stockholders’ equity | 66,481 | 54,155 | |||||
| Total liabilities and stockholders’ equity | $ | 106,263 | $ | 64,113 | |||
| Digirad Corporation Reconciliation of Non-GAAP Financial Measures (Unaudited) | |||||||||||||||||
| Three Months Ended December 31, | Twelve Months Ended December 31, | ||||||||||||||||
| (in thousands, except per share amounts) | 2016 | 2015 | 2016 | 2015 | |||||||||||||
| Net income | $ | 1,978 | $ | 678 | $ | 14,302 | $ | 21,640 | |||||||||
| Acquired intangible amortization | 578 | 131 | 2,313 | 496 | |||||||||||||
| Acquisition related contingent consideration valuation adjustment(1) | (56 | ) | 113 | (64 | ) | (60 | ) | ||||||||||
| Investment impairment loss(2) | — | 278 | 414 | 278 | |||||||||||||
| Transaction and integration costs of DMS Health Technologies(3) | 173 | 595 | 1,921 | 1,338 | |||||||||||||
| Goodwill impairment | 338 | — | 338 | — | |||||||||||||
| Income tax items(4) | 25 | (446 | ) | (12,071 | ) | (19,145 | ) | ||||||||||
| Non-GAAP Adjusted net income | $ | 3,036 | $ | 1,349 | $ | 7,153 | $ | 4,547 | |||||||||
| Net income per share - diluted(5) | $ | 0.10 | $ | 0.03 | $ | 0.71 | $ | 1.10 | |||||||||
| Acquired intangible amortization | 0.03 | 0.01 | 0.12 | 0.03 | |||||||||||||
| Acquisition related contingent consideration valuation adjustment(1) | — | 0.01 | — | — | |||||||||||||
| Investment impairment loss(2) | — | 0.01 | 0.02 | 0.01 | |||||||||||||
| Transaction and integration costs of DMS Health Technologies(3) | 0.01 | 0.03 | 0.10 | 0.07 | |||||||||||||
| Goodwill impairment | 0.02 | — | 0.02 | — | |||||||||||||
| Income tax items(4) | — | (0.02 | ) | (0.60 | ) | (0.97 | ) | ||||||||||
| Non-GAAP Adjusted net income per share - diluted(5) | $ | 0.15 | $ | 0.07 | $ | 0.36 | $ | 0.23 | |||||||||
| Three Months Ended December 31, | Twelve Months Ended December 31, | ||||||||||||||||
| (in thousands) | 2016 | 2015 | 2016 | 2015 | |||||||||||||
| Net income | $ | 1,978 | $ | 678 | $ | 14,302 | $ | 21,640 | |||||||||
| Acquisition related contingent consideration valuation adjustment(1) | (56 | ) | 113 | (64 | ) | (60 | ) | ||||||||||
| Investment impairment loss(2) | — | 278 | 414 | 278 | |||||||||||||
| Transaction and integration costs of DMS Health Technologies(3) | 173 | 595 | 1,921 | 1,338 | |||||||||||||
| Goodwill impairment | 338 | — | 338 | — | |||||||||||||
| Depreciation and amortization | 2,552 | 690 | 9,889 | 2,441 | |||||||||||||
| Stock-based compensation | 270 | 166 | 1,024 | 616 | |||||||||||||
| Interest income | (2 | ) | (7 | ) | (14 | ) | (39 | ) | |||||||||
| Interest expense | 322 | 19 | 1,426 | 63 | |||||||||||||
| Income tax benefit | (194 | ) | (425 | ) | (12,417 | ) | (19,123 | ) | |||||||||
| Non-GAAP Adjusted EBITDA | $ | 5,381 | $ | 2,107 | $ | 16,819 | $ | 7,154 | |||||||||
| (1) Reflects fair value adjustment to estimate of contingent consideration related to acquisitions. |
| (2) Reflects impairment losses related to investment in Perma-Fix Medical. Amount consists of a write-down of the investment to its fair market value that was considered other than temporary. |
| (3) Reflects diligence, transaction, and integration costs related to the acquisition of DMS Health Technologies. |
| (4) Reflects income tax effect for adjusted financial data and acquisition related income tax adjustments, and release of previously reserved net operating loss carryforwards. |
| (5) Per share amounts are computed independently for each discrete item presented. Therefore, the sum of the quarterly per share amounts will not necessarily equal to the total for the year, and sum of individual items may not equal the total. |
| Digirad Corporation Reconciliation of Non-GAAP Financial Measures (Unaudited) | |||||||||||||||||||||
| Three Months Ended | |||||||||||||||||||||
| (in thousands, except per share amounts) | December 31, 2015 | March 31, 2016 | June 30, 2016 | September 30, 2016 | December 31, 2016 | ||||||||||||||||
| Net income (loss) | $ | 678 | $ | 11,609 | $ | 998 | $ | (283 | ) | $ | 1,978 | ||||||||||
| Acquired intangible amortization | 131 | 577 | 578 | 578 | 578 | ||||||||||||||||
| Acquisition related contingent consideration valuation adjustment(1) | 113 | — | (3 | ) | (5 | ) | (56 | ) | |||||||||||||
| Investment impairment loss(2) | 278 | — | — | 414 | — | ||||||||||||||||
| Transaction and integration costs of DMS Health Technologies(3) | 595 | 1,450 | 171 | 127 | 173 | ||||||||||||||||
| Goodwill impairment | — | — | — | — | 338 | ||||||||||||||||
| Income tax items(4) | (446 | ) | (12,333 | ) | 67 | 170 | 25 | ||||||||||||||
| Non-GAAP Adjusted net income | $ | 1,349 | $ | 1,303 | $ | 1,811 | $ | 1,001 | $ | 3,036 | |||||||||||
| Net income (loss) per share - diluted(5) | $ | 0.03 | $ | 0.58 | $ | 0.05 | $ | (0.01 | ) | $ | 0.10 | ||||||||||
| Acquired intangible amortization | 0.01 | 0.03 | 0.03 | 0.03 | 0.03 | ||||||||||||||||
| Acquisition related contingent consideration valuation adjustment(1) | 0.01 | — | — | — | — | ||||||||||||||||
| Investment impairment loss(2) | 0.01 | — | — | 0.02 | — | ||||||||||||||||
| Transaction and integration costs of DMS Health Technologies(3) | 0.03 | 0.07 | 0.01 | 0.01 | 0.01 | ||||||||||||||||
| Goodwill impairment | — | — | — | — | 0.02 | ||||||||||||||||
| Income tax items(4) | (0.02 | ) | (0.62 | ) | — | 0.01 | — | ||||||||||||||
| Non-GAAP Adjusted net income per share - diluted(5) | $ | 0.07 | $ | 0.07 | $ | 0.09 | $ | 0.05 | $ | 0.15 | |||||||||||
| Three Months Ended | |||||||||||||||||||||
| (in thousands) | December 31, 2015 | March 31, 2016 | June 30, 2016 | September 30, 2016 | December 31, 2016 | ||||||||||||||||
| Net income (loss) | $ | 678 | $ | 11,609 | $ | 998 | $ | (283 | ) | $ | 1,978 | ||||||||||
| Acquisition related contingent consideration valuation adjustment(1) | 113 | — | (3 | ) | (5 | ) | (56 | ) | |||||||||||||
| Investment impairment loss(2) | 278 | — | — | 414 | — | ||||||||||||||||
| Transaction and integration costs of DMS Health Technologies(3) | 595 | 1,450 | 171 | 127 | 173 | ||||||||||||||||
| Goodwill impairment | — | — | — | — | 338 | ||||||||||||||||
| Depreciation and amortization | 690 | 2,465 | 2,383 | 2,489 | 2,552 | ||||||||||||||||
| Stock-based compensation | 166 | 223 | 257 | 274 | 270 | ||||||||||||||||
| Interest income | (7 | ) | (5 | ) | (4 | ) | (3 | ) | (2 | ) | |||||||||||
| Interest expense | 19 | 375 | 383 | 345 | 322 | ||||||||||||||||
| Income tax expense (benefit) | (425 | ) | (12,461 | ) | 37 | 202 | (194 | ) | |||||||||||||
| Non-GAAP Adjusted EBITDA | $ | 2,107 | $ | 3,656 | $ | 4,222 | $ | 3,560 | $ | 5,381 | |||||||||||
| (1) Reflects fair value adjustment to estimate of contingent consideration related to acquisitions. |
| (2) Reflects impairment losses related to investment in Perma-Fix Medical. Amounts consist of impairment of a Supply Agreement entered into between the two parties, a loss related to the initial excess of the transaction price over fair value and a write-down of the investment to its fair market value that was considered other than temporary. |
| (3) Reflects diligence, transaction, and integration costs related to the acquisition of DMS Health Technologies. |
| (4) Reflects income tax effect for adjusted financial data and acquisition related income tax adjustments, and release of previously reserved net operating loss carryforwards. |
| (5) Per share amounts are computed independently for each discrete item presented. Therefore, the sum of the quarterly per share amounts will not necessarily equal to the total for the year, and sum of individual items may not equal the total. |
| Digirad Corporation Supplemental Debt Information (Unaudited) | |||||
| The following table reflects outstanding principal balances and interest rates under the Company's credit facility at December 31, 2016: | |||||
| (in thousands) | Balance | Interest Rate | |||
| Term A(1) | $ | 17,382 | 3.15 | % | |
| Term B(2) | 4,581 | 5.65 | % | ||
| Revolver | — | 2.69 | % | ||
| Total borrowing | $ | 21,963 | |||
| (1) Term A amortizes over a 7-year period with scheduled amortization ending in January 2021, with the remaining amount due in a balloon payment. |
| (2) Term B amortizes over a 3-year period with scheduled amortization ending in January 2019. Through December 31, 2016, the Company has made three extra payments in the same amount as the scheduled payments. |
| Digirad Corporation Supplemental Cash Flow Information (Unaudited) | |||||||||
| Twelve Months Ended December 31, | |||||||||
| (in thousands) | 2016 | 2015 | 2014 | ||||||
| Net cash provided by operating activities | $ | 10,834 | $ | 3,720 | $ | 4,280 | |||
| Purchases of property and equipment | $ | 6,185 | $ | 1,424 | $ | 1,258 | |||